Literature DB >> 7873136

Antidepressants: partial response in chronic depression.

J Fawcett1.   

Abstract

Although most studies of chronic depression show significant improvements with antidepressants versus placebo, the average Hamilton Depression Rating Scale results attained in the active-treatment group range between 10 and 14, suggesting that many patients only partially responded and failed to reach premorbid levels of symptom remission. Studies on the fate of these patients suggest that they are much more vulnerable to relapse, work impairment and suicide. Thus, partial response may be one form of treatment resistance, falling between total failure of response in a minority of patients, and a tendency to relapse or recur despite adequate maintenance treatment. Further study is needed to address the problem of improving the quality of response and attempting to reduce the detrimental effects of depressive illness in terms of relapse and recurrence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873136

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  6 in total

Review 1.  Improving the treatment of depression in primary care: problems and prospects.

Authors:  R G Moore
Journal:  Br J Gen Pract       Date:  1997-09       Impact factor: 5.386

2.  Chronic depression: a case series of 203 outpatients treated at a private practice.

Authors:  F Benazzi
Journal:  J Psychiatry Neurosci       Date:  1998-01       Impact factor: 6.186

Review 3.  Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Authors:  Sandra J Drozdz; Akash Goel; Matthew W McGarr; Joel Katz; Paul Ritvo; Gabriella F Mattina; Venkat Bhat; Calvin Diep; Karim S Ladha
Journal:  J Pain Res       Date:  2022-06-15       Impact factor: 2.832

Review 4.  Partial remission, residual symptoms, and relapse in depression.

Authors:  E S Paykel
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

5.  New statistical proposals to evaluate the benefit/risk ratio of long-term treatment of depression: application to a one-year double-blind study comparing medifoxamine with fluoxetine.

Authors:  P Lehert; M F Poirier-Littre; D Pringuey; A Galinowski
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

6.  Dysthymic disorder: forlorn and overlooked?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2009-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.